Performance of the Roche Total Mycophenolic Acid[®] assay on the Cobas Integra 400[®], Cobas 6000[®] and comparison to LC-MS/MS in liver transplant patients

An-Sofie C. Decavele, Niels Favoreel, Fien Vander Heyden and Alain G. Verstraete*

Department of Clinical Chemistry, Ghent University Hospital, Ghent, Belgium

Abstract

Background: Mycophenolic acid (MPA) is an immunosuppressant for which therapeutic drug monitoring (TDM) is performed for optimal prophylaxis and avoidance of toxicity in transplant patients. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is ideally suited for TDM of MPA. There have been several method comparisons of the Roche Total MPA assay, but none have been performed with respect to liver transplant patients.

Methods: We validated the Roche Total MPA assay on the Cobas Integra 400 and Cobas 6000 and compared it to a validated LC-MS/MS (API 2000[™]) method. Fifty-five EDTA plasma samples from liver transplant patients were measured with the Roche assay on these platforms and compared to the LC-MS/MS results.

Results: Validation of the LC-MS/MS, Cobas Integra 400 and 6000 was performed with good results. The LC-MS/MS/Integra 400/Cobas 6000 were linear up to 30, 15 and 17 mg/L, respectively. Imprecision was <10% for LC-MS/MS and <7% for the Roche assay on both platforms. The samples showed good agreement with LC-MS/MS. Passing-Bablok regression analysis showed Cobas Integra (mg/L) = $1.02 \times \text{LC-MS/MS (mg/L)} - 0.50$ and Cobas 6000 (mg/L) = $0.98 \times \text{LC-MS/MS} - 0.47$.

Conclusions: The Roche Total Mycophenolic Acid-assay is suitable for measuring total MPA in plasma from liver transplant patients and is a good alternative for LC-MS/MS.

Keywords: enzyme assay; inosine monophosphate dehydrogenase; liquid chromatography-tandem mass spectrometry; liver transplantation; mycophenolic acid.

*Corresponding author: Prof. Alain Verstraete, Laboratory of Toxicology, Ghent University Hospital, Department of Laboratory Medicine, Ghent University, Department of Clinical Chemistry, De Pintelaan 185, 9000 Ghent, Belgium
Phone: +32 9 332 34 07, Fax: +32 9 332 49 85,
E-mail: alain.verstraete@ugent.be
Received November 10, 2010; accepted February 27, 2011;
previously published online June 13, 2011

Introduction

In transplant patients, mycophenolic acid (MPA) has a prominent role in the prophylaxis of acute rejection. The drug is administered to kidney, heart, liver, lung, bowel, pancreas and bone marrow transplant patients. MPA is commonly used in combination with corticosteroids and calcineurin inhibitors, such as tacrolimus and cyclosporine, or in combination with the macrolide antibiotic sirolimus (1).

Two forms are widely available: the prodrug mycophenolate mofetil (MMF) and the enteric-coated mycophenolate sodium (EC-MPS). MMF and EC-MPS are absorbed from the gastrointestinal tract and hydrolyzed, resulting in a high MPA bioavailability (>90%). MPA is the active metabolite of MMF. MPA is metabolized in the liver to the pharmacologically inactive phenolic glucuronide (MPAG), a phenolic glucoside and the in vitro active acyl glucuronide (AcMPAG) (2, 3). The pharmacokinetics of MPA are complicated by the enterohepatic circulation, giving rise to a second peak of MPA 6–12 h following oral administration. Furthermore, the pharmacokinetics are influenced by the high protein binding of MPA; 97% of MPA is bound to plasma albumin and only the free fraction has immunosuppressive action (4). Therapeutic drug monitoring (TDM) of MPA may minimize the risk for rejection after transplantation. Despite insufficient evidence to provide unequivocal guidelines on the requirement for MPA monitoring in liver transplantation, the latest Consensus Report indicated six conditions where TDM of MPA is recommended (1). Monitoring the area under the curve (AUC) has been recommended, an $\text{AUC}_{0-12 \text{ h}} > 30 \text{ mg/L/h}$ and $< 60 \text{ mg/L/h}$ provides optimal prophylaxis (1, 5).

The standard procedures to quantify MPA currently used are high performance liquid chromatography (HPLC) and liquid chromatography-tandem mass spectrometry (LC-MS/MS). The use of the Enzyme Multiplied Immunoassay Technique (EMIT[®]) and Cloned Enzyme Donor Immunoassay method (CEDIA[®]) for MPA have not gained widespread use, mainly because of the cross-reactivity with the metabolite AcMPAG (6–12). The use of the Roche Total Mycophenolic Acid[®] assay has previously been compared with HPLC and LC-MS/MS methods for renal and cardiac transplant patients (13–16). However, to our knowledge there have been no studies about the performance in liver transplant patients. In this study, we evaluated the Roche Total Mycophenolic Acid[®] assay (Roche Diagnostics, IN, USA) on the COBAS Integra[®] 400 and Cobas 6000[®] (Roche Diagnostics, IN, USA) and compared it with LC-MS/MS.

Materials and methods

Sample collection

Fifty-five EDTA plasma samples from liver transplant patients at our university hospital were collected. These samples were analyzed on the three platforms on the same day. The samples were anonymized leftover samples from routine analysis.

Enzyme assay

The Roche Total Mycophenolic Acid[®] assay was performed on the Cobas Integra[®] 400 and Cobas 6000[®] (Roche Diagnostics, IN, USA) according to the manufacturer's instructions. Reactions conditions are detailed in Figure 1. We used serum-based total MPA calibrators and total MPA controls from Roche Diagnostics for all assays. The calibrators consisted of six levels: 0, 1, 3, 5, 10 and 15 mg/L. The controls consisted of three levels: 0.869 mg/L (range 0.695–1.043 mg/L), 3.58 mg/L (range 2.86–4.30 mg/L) and 12.5 mg/L (range 10.1–14.9 mg/L).

LC-MS/MS

LC-MS/MS was performed with an API 2000[™] (Applied Biosystems, Foster City, CA, USA) with an electrospray ionization (ESI) inlet. The mobile phase was a gradient of 2 mmol/L ammonium acetate (Fluka, Buchs, Switzerland) in water and methanol (Biosolve BV, Valkenswaard, The Netherlands). The column used was an Agilent[®] Zorbax RP-C18, 2.1×30 mm (Agilent Technologies Inc., Santa Clara, CA, USA). Precipitation fluid (200 µL) containing 3.33 mg/L internal standard mycophenolic acid carboxyether (Roche Bioscience, Palo Alto, CA, USA) in methanol (Biosolve BV, Valkenswaard, The Netherlands) and zinc sulphate 0.3 mol/L (Merck nv, Overijse, Belgium) (70/30 vol:vol) was added to the EDTA plasma samples (50 µL). After vortexing for 1 min, 5 min centrifugation at 12,000 rpm, the supernatant (60 µL) was transferred into a vial. The injection volume was 3 µL. The system consisted of an Agilent[®] 1100 LC Quaternary Pump, thermostated to 40°C by an Agilent Column Oven. During the acquisition there was a flow rate of 500 µL/min using solvent A (2 mmol/L NH₄⁺ in water) and solvent B (2 mmol/L NH₄⁺ in methanol). An eluent gradient was used, starting with 1.5 min 90% A and 10% B, 9.5 min 5% A and 95% B and ending with 12 min 90% A and 10% B. We used a multiple reaction monitoring (MRM) acquisition method of 12 min. The following transitions were monitored: 438.3/303.0

(NH₄⁺-MPAC), 421.1/303.2 (MPAC), 338.2/207.0 (NH₄⁺-MPA, quantifier transition), 321.1/303.1 (MPA) and 321.1/159.0 (qualifier transition). The ammonium adduct of MPA and MPAC was used for sample quantification.

Statistical analysis

We used MedCalc[®] (MedCalc Software, Mariakerke, Belgium) and Microsoft Office Excel[®] (Microsoft Corporation, Redmond, WA, USA). A Grubbs test, a one sided F-test and a one-way ANOVA test were used in the LC-MS/MS method validation. Passing-Bablok regression analysis was performed in the method comparison.

LC-MS/MS method validation

The LC-MS/MS method for the quantification of total mycophenolate (tMPA) in plasma, was validated according to a published experimental design (17). This design includes a pre-validation and a main validation phase.

In the pre-validation phase, absence of interferences (selectivity), matrix effects, processed sample stability and linearity were investigated. Ion suppression/enhancement (ME), extraction efficiency (RE) and process efficiency (PE) were measured as described by Matuszewski et al. (18). Linearity was assessed after removing outliers with the Grubbs test (19), and the check for homogeneity of variance was performed with a one-sided F-test between the variances at the highest and lowest concentration values (17). A p-value <0.05 was considered significant.

For the main validation, the Roche total MPA calibrators and control material were run over an 8 day period in duplicate, with a new calibration curve obtained each day. Using a one-way ANOVA with each day as the grouping variable allowed the calculation of intra- and inter-assay precision, and total assay precision expressed as percent coefficient of variation (CV) (17). In order to measure the variability of the calibration curve, the imprecision and accuracy characteristics were determined, as well as the lower limit of quantification (LLOQ). The imprecision and accuracy was deemed acceptable, at respectively, 10% and 15%, and the CV and bias at LLOQ at 20% (20). The dilution experiment was performed with a serial dilution (dilution 2, 4, 8) with bovine serum on a spiked plasma pool (60 mg/L). The plasma pools underwent three freeze/thaw cycles.

Method validation on Cobas Integra 400 and Cobas 6000

In order to assess linearity, 11 dilutions were made spanning 0%–100% of a high concentration pool (28.5 mg/L). The lower limit of detection (LLOD) was measured by running 21 replicates of three blank samples on three different days. The LLOQ was determined using a functional sensitivity approach. Ten aliquots of five patient samples with total MPA concentrations between 0.45 and 0.85 mg/L were analyzed on 10 different days. Imprecision characteristics were determined by analyzing the Roche total MPA controls, Roche total MPA calibrator B (1 mg/L) and three total MPA plasma pools (0.8, 2.5 and 9.0 mg/L), in triplicate for 21 days. The criteria from Roche Diagnostics were used to evaluate the imprecision: SD ≤ 0.07 up to a concentration of 1 mg/L and CV ≤ 7.0% at concentrations > 1 mg/L.

Method comparison

Only measurements up to 15 mg/L could be used for comparison because the Cobas Integra reports all results >15 mg/L as

Figure 1 Schematic overview of the enzymatic reaction of the Roche Total Mycophenolic Acid[®] assay.

IMP, inosine monophosphate; NAD, nicotinamide adenine dinucleotide; MPA, mycophenolic acid; IMPDH-II, type 2 inosine monophosphate dehydrogenase; XMP, xanthosine monophosphate. IMP is enzymatically converted into XMP through the enzyme IMPDH-II. This step requires conversion of NAD to NADH. MPA blocks the enzymatic process of IMP into XMP. When MPA is present, there is no formation of XMP and hence no release of NADH. In the assay from Roche, the formation of NADH is measured at 340 nm. NADH production is inversely proportional to the concentration of MPA.

'> 15 mg/L'. Higher concentrations can be diluted with blank plasma or diluent, but we did not evaluate this. Forty-seven of 55 samples were <15 mg/L, the other eight samples were excluded from the method comparison.

For evaluating the degree of agreement, Passing-Bablok regression analysis was used to determine proportional and constant bias by checking of the 95% confidence intervals (CI) of the slope and the intercept. If one was not included in the 95% CI of the slope, there is constant error, and if zero was not included in the 95% CI of the intercept, proportional error is present.

Results

LC-MS/MS method validation

Pre-validation No interferences were detected with 10 different blank plasma samples and two zero samples. Possible interference from cyclosporine, tacrolimus, sirolimus and everolimus was tested at concentrations of, respectively, 514, 16.7, 20.4 and 8.48 µg/L. The compounds did not cause any interference.

The ME, RE and PE were, respectively, 87%, 97% and 85% for the low concentration, and 85%, 98% and 83% for the high concentration. Our method showed similar results as Shen et al. (ME 90.7%–94.3%; RE 90.6%–93.4%) (21).

There were no obvious changes in stability of processed samples during the analysis. The within-group CV at 0.63 mg/L was 5.2%, and at 3.14 mg/L was 4.4%. Ranging from 0 to 30 mg/L, the linearity was determined after identifying one outlier and performing a one-sided F-test between the variances at the 6 mg/L pool and the 30 mg/L pool. The variance ratio was 2.36 ($p=0.363$), the variance over the calibration range is not homogeneous and therefore a weighted regression model was used (weighting factor $1/x$, $r=0.99$).

Main validation Variability of the calibration curve: two concentration levels in our six-point calibration curve were too high. The target concentrations of 1 mg/L and 5 mg/L were not within the 95% confidence interval of our measured mean value, respectively [1.0068–1.0832] and [5.0073–5.2802]. The blank calibrator was excluded from this experiment, the other five concentration levels were: 1, 3, 5, 10, 15 mg/L, and the between run CVs were respectively: 4.4, 2.6, 3.2, 2.9, 1.9%. The within group CV was 1.6%. Bias ranged from 0.04% to 4.5%.

Results of accuracy and imprecision are given in Table 1. At each QC level, the CV and bias was <10%. The LLOQ was determined by analyzing two spiked plasma pools at two different concentrations (0.18–0.36 mg/L). The criterion of <20% CV was met for both concentrations. The LLOQ was therefore set to 0.18 mg/L.

The within group CV at dilution 1 (60 µg/L), 2 (30 µg/L), 4 (15 µg/L), 8 (7.5 µg/L) were respectively 6.3%, 8.8%, 6.2%, 8.4%. Linearity was good up to 30 mg/L. Above this concentration, the test reached a plateau, with a high negative bias (19%) at 60 mg/L. The 24 results at each concentration all gave <10% CV.

Method validation on Cobas Integra 400 and Cobas 6000

The linearity could only be measured partially on the Cobas Integra 400, where all results >15 mg/L are expressed as '> 15'. The bias was <10% for all measured concentrations and linearity was good between 0.4 and 15 mg/L. On the Cobas 6000 the method was not linear up to 28.5 mg/L, but up to 17 mg/L only. Analyzing blank samples on the Cobas Integra yielded an LLOD that was <0.4 mg/L. On the Cobas 6000, all results were lower than the LLOQ (0.45 mg/L) with a mean LLOD of 0.06 mg/L. The functional sensitivity was evaluated using five samples with mean concentrations ranging from 0.45 to 0.85 mg/L, the CV for the Cobas Integra ranged between 5.3% and 12.8% and for the Cobas 6000 between 5.1% and 13.8%. The LLOQ was 0.45 mg/L for the Cobas Integra and 0.48 mg/L for the Cobas 6000.

The Cobas Integra and the Cobas 6000 met the Roche imprecision criteria for all levels, except for calibrator B on the Cobas 6000 ($SD=0.13$). There were no significant differences in CV or bias between Cobas Integra 400 and Cobas 6000.

Method comparison

Figures 2 and 3 show good the agreement between LC-MS/MS and the Cobas Integra 400 and Cobas 6000. The range of measurement was 1.19–14 mg/L (median, 5.35 mg/L) for LC-MS/MS, 0.72–14.68 mg/L (median, 5.02 mg/L) for Integra and 0.63–14.16 mg/L (median, 4.89 mg/L) for Cobas 6000. Passing-Bablok regression analysis yielded an equation of Cobas Integra 400 (mg/L) = $1.02 \times \text{LC-MS/MS (mg/L)}$

Table 1 Imprecision and accuracy characteristics of the LC-MS/MS method. Quality control materials were run over 8 days in duplicate (a and b).

	Low		Medium		High	
	QC Ia	QC Ib	QC IIa	QC IIb	QC IIIa	QC IIIb
Target, µg/mL	0.87	0.87	3.58	3.58	12.50	12.50
Mean, µg/mL (n=8)	0.84	0.86	3.50	3.64	12.26	12.59
Bias, %	-4.0	-0.5	-2.2	1.8	-1.9	0.7
Intra-assay CV, %		3.5		5.5		3.1
Inter-assay CV, %		2.9		0.0		0.0
Total precision CV, %		4.6		5.3		2.7

SD, standard deviation; CV, coefficient of variation.

Figure 2 Passing-Bablok regression analysis of the Cobas Integra 400 with LC-MS/MS.

Cobas Integra 400 (mg/L) = $1.02 \times \text{LC-MS/MS (mg/L)} - 0.50$ ($r^2 = 0.98$). The full line is the regression-line. The two dashed lines show the 95% confidence interval and the point line is slope = 1.

Figure 3 Passing-Bablok regression analysis of Cobas 6000 with LC-MS/MS.

Cobas 6000 (mg/L) = $0.98 \times \text{LC-MS/MS (mg/L)} - 0.47$ ($r^2 = 0.98$). The full line is the regression-line. The two dashed lines show the 95% confidence interval and the point line is slope = 1.

–0.50 (95% CI intercept: –0.66 to –0.281; 95% CI slope: 0.96–1.03) (Figure 2) and Cobas 6000 (mg/L) = $0.98 \times \text{LC-MS/MS (mg/L)} - 0.47$ (95% CI intercept: –0.72 to –0.324; 95% CI slope: 0.99–1.06) (Figure 3). The mean absolute difference was, respectively, 0.45 mg/L and 0.26 mg/L (Figures 4 and 5). These results indicate that there is constant error, but no proportional error.

Discussion

There is a good agreement between results of the LC-MS/MS and Cobas Integra or Cobas 6000. As indicated in Table 2, our regression analysis is similar to other studies (13–15,

Figure 4 Bland-Altman plot of the Cobas Integra compared to LC-MS/MS.

The Bland-Altman plot of the Cobas Integra compared to LC-MS/MS demonstrates that Cobas Integra 400 measures approximately 0.26 mg/L lower than LC-MS/MS. The two point-dashed lines are the 95% confidence interval of mean of differences. The point line is the line of equality.

Figure 5 Bland-Altman plot of the Cobas 6000 compared to LC-MS/MS.

Bland-Altman plot of the Cobas 6000 compared to LC-MS/MS demonstrates that the Cobas 6000 measures approximately 0.45 mg/L lower than LC-MS/MS. The two point-dashed lines are the 95% confidence interval of mean of differences. The point line is the line of equality.

22, 23). However, in our study, a higher intercept was obtained. The intercepts of the Cobas Integra 400 (–0.50) and the Cobas 6000 (–0.47) were similar. Problems with LC-MS/MS, such as falsely lowered results due to ion suppression, or falsely elevated results by in-source fragmentation of the phenolic glucuronide have been described (24). The Bland-Altman plots in Figures 4 and 5 indicate that the enzymatic assays yield lower results than the LC-MS/MS, for the Cobas 6000 approximately 0.45 mg/L and the Cobas Integra 0.26 mg/L. However, the observed percent ion suppression (14%) in our study could not explain the lower intercept, and

the in-source fragmentation of the phenolic glucuronide was not present in our method. Moreover, MPA and MPAG were baseline separated. Besides this constant error, the slopes and coefficients of the regression analysis were comparable with other studies. Together with other studies, summarized in Table 2, there is sufficient proof that the Roche assay can quantitatively measure total MPA in liver transplant patients. However, further studies are needed to confirm the negative bias.

A well described problem for the EMIT and CEDIA method is the overestimation of, respectively, 25% and 36% of the MPA concentration at the LLOQ concentration. This could partly be explained by cross-reactivity with AcMPAG (1). For the IMPDH (type 2 inosine monophosphate dehydrogenase)-based enzyme inhibition enzyme assays (Roche), MPA overestimation by AcMPAG was low (<5%) and was considered as clinically irrelevant (13). In our study, too few samples at such concentrations were included in the study to confirm these findings.

The most important advantage of chromatography is the possibility to measure the MPA metabolites. Measurement of the metabolites is a growing concern, especially in liver and renal compromised patients. The largest CVs for AUC and predose concentrations were found in postoperative liver transplant patients and in renal transplant patients with early graft dysfunction. For liver transplant patients this is probably due to hyperbilirubinemia, uremia and hypoalbuminemia. MPA is 97% bound to albumin, while MPAG is only 82% bound to albumin. MPAG itself is not pharmacologically active, the formation of an O- or N-glucuronides is a com-

mon pathway in phase II drug metabolism and is considered a detoxification mechanism (25). However, high MPAG concentrations can augment the free fraction of MPA by displacement effects on albumin (26). In case of liver transplant patients, measuring high MPAG can indicate an increase in free MPA. Renal insufficiency is characterized by a higher free MPA fraction and lower total MPA due to restrictive clearance (27). Besides the need for measuring both MPA and MPAG, AcMPAG should also be measured. The immunosuppressant action of MPA is an uncompetitive and reversible inhibition of IMPDH, resulting in a decreased de novo synthesis of guanine nucleotides and impaired nucleic acid synthesis (25). AcMPAG seems to inhibit IMPDH in vitro, but its possible immunosuppressive activity needs to be further investigated. In contrast, AcMPAG may be involved in the development of gastrointestinal side-effects associated with MPA. Wieland et al. demonstrated in vitro that an acyl glucuronide has the potential to induce a proinflammatory reaction in human leukocytes. As diarrhea and intestinal ulceration may result from an inflammatory reaction, and AcMPAG would promote release of cytokines in vivo, AcMPAG could contribute to these toxic actions of MPA (2, 25). Many chromatographic methods to measure free MPA, MPAG and AcMPAG have been described (21, 26, 28–33). The downside is that they all require a significant amount of knowledge, sophisticated equipment and trained technicians, and are therefore expensive and time-consuming.

The latest consensus report on TDM of MPA advises measurement of total MPA in limited sampling strategies for solid organ transplants. Measuring free MPA or metabolites

Table 2 Summary of published method comparison studies between measurement of total MPA with the enzymatic assay and chromatographic methods.

Author	Year	Group specifications	n	Linear regression	Correlation	Reference method	Analyzer
Domke et al. (22) (abstract)	2005	Total MPA	96	$1.061x + 0.11$	$r = 0.99$	LC-MS/MS	Cobas Integra
Marquet et al. (14) (abstract)	2006	Adult renal + tacrolimus	270	$1.044x + 0.03$	$r^2 = 0.97$	LC-MS/MS	Cobas Integra
		Adult lung + tacrolimus	109	$1.025x + 0.059$	$r^2 = 0.96$	LC-MS/MS	Cobas Integra
		Adult renal + sirolimus	240	$1.105x - 0.144$	$r^2 = 0.97$	LC-MS/MS	Cobas Integra
		Pediatric renal + cyclosporin	115	$1.0x + 0.06$	$r^2 = 0.96$	LC-MS/MS	Cobas Integra
		Adult renal + cyclosporin	119	$1.208x - 0.109$	$r^2 = 0.98$	LC-MS/MS	Cobas Integra
Luthe et al. (23) (poster)	2006	Renal/cardiac transplant	87	$1.055x - 0.010$	$r = 0.98$	LC-MS/MS	Cobas Integra 800
		Renal/cardiac transplant	87	$1.045x + 0.1011$	$r = 0.97$	LC-MS/MS	Cobas C501
		Renal/cardiac transplant	65	$1.12x + 0.009$	$r = 0.98$	LC-MS/MS	Cobas Integra 400
Brandhorst et al. (13)	2008	Renal transplant	174	$1.09x - 0.13$	$r = 0.99$	HPLC-UV	Cobas Integra 800
		–	87	$1.06x - 0.01$	$r = 0.98$	LC-MS/MS	Cobas Integra 800
		Renal transplant	190	$1.01x + 0.04$	$r = 0.99$	LC-MS/MS	Cobas C501
		Renal transplant	65	$1.12x + 0.01$	$r = 0.98$	LC-MS/MS	Cobas Integra 400
		Renal/cardiac transplant	265	$1.01x + 0.06$	$r = 0.99$	HPLC-UV	Cobas Integra 400
		Renal/cardiac transplant	60	$1.17x - 0.17$	$r = 0.98$	HPLC-UV	Cobas Integra 400
		Tacrolimus	158	$1.01x + 0.08$	$r = 0.99$	–	–
		Cyclosporine	32	$0.99x + 0.01$	$r = 1.00$	–	–
		Renal transplant	1986	$1.009x - 0.05$	$r = 0.99$	LC-MS/MS	Cobas Integra 800
Van Gelder et al. (16)	2009	Cyclosporine	242	$1.037x - 1.046$	$r = 0.99$	LC-MS/MS	Cobas Integra 800
		Tacrolimus	462	$1.020x - 0.626$	$r = 0.99$	LC-MS/MS	Cobas Integra 800
		Renal transplant	694	$1.079x - 0.031$	$r = 0.98$	LC-MS/MS	Cobas Integra 400
Marquet et al. (15)	2009	Lung transplant	109	$1.045x + 0.048$	$r = 0.99$	LC-MS/MS	Cobas Integra 400

Linear regression: y, Roche Total MPA assay on mentioned automatic platforms; x, LC-MS/MS or HPLC-UV. Cobas C501, Cobas 6000.

of MPA is so far not included in the consensus report (1). Concentration-controlled MPA dosing is only needed for patients who are at immunologic risk, patients with altered renal, hepatic or bowel function and patients undergoing minimization or withdrawal of therapy. However, there is still no evidence that TDM of MPA provides benefit in graft outcome or patient survival (1).

In conclusion, the Roche assay is a good alternative for LC-MS/MS or HPLC-UV method if total MPA dosing is sufficient. The observed constant bias of 0.5 mg/L needs to be confirmed in further studies. We confirmed that the total MPA assay of Roche performs as well as LC-MS/MS, and is therefore a reliable method to measure total MPA in liver transplant patients.

Acknowledgments

The Cobas MPA reagent, calibrators and controls were kind gifts from Roche®. This study was supported by Roche Diagnostics.

Conflict of interest statement

Authors' conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research support played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

References

- Kuypers DR, Meur YL, Cantarovich M, Tredger MJ, Tett SE, Cattaneo D, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. *Clin J Am Soc Nephrol* 2010;5:341–58.
- Shaw LM, Korecka M, Venkataraman R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis of rational monitoring strategies. *Am J Transplant* 2003;3:534.
- Korecka M, Nikolic D, van Breemen RB, Shaw LM. The apparent inhibition of inosine monophosphate dehydrogenase by mycophenolic acid glucuronide is attributable to the presence of trace quantities of mycophenolic acid. *Clin Chem* 1999; 45:1047–50.
- Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. *Clin Pharmacokinet* 1998; 34:429.
- Shaw LM, Holt DW, Oellerich M, Meiser B, van GT. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. *Ther Drug Monit* 2001;23: 305–15.
- Beal JL, Jones CE, Taylor PJ, Tett SE. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay. *Ther Drug Monit* 1998;20:685–90.
- Brunet M, Oppenheimer F, Martorell J, Vilardell J, Carreno MC, Carrillo M, et al. Mycophenolic acid monitoring: evaluation of the EMIT MPA immunoassay in kidney and lung transplantation. *Transplant Proc* 1999;31:2275–6.
- Shipkova M, Schutz E, Armstrong VW, Niedmann PD, Wieland E, Oellerich M. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. *Transplant Proc* 1999;31: 1135–7.
- Vogl M, Weigel G, Seebacher G, Griesmacher A, Laufer G, Muller MM. Evaluation of the EMIT Mycophenolic acid assay from Dade Behring. *Ther Drug Monit* 1999;21:638–43.
- Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, et al. Comparison of the EMIT immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. *Clin Chem* 2002;48:517–25.
- Shipkova M, Schutz E, Besenthal I, Fraunberger P, Wieland E. Investigation of the cross-reactivity of mycophenolic acid glucuronide metabolites and of mycophenolate mofetil in the CEDIA MPA assay. *Ther Drug Monit* 2009;32:79–85.
- Westley IS, Ray JE, Morris RG. CEDIA mycophenolic acid assay compared with HPLC-UV in specimens from transplant recipients. *Ther Drug Monit* 2006;28:632–6.
- Brandhorst G, Marquet P, Shaw LM, Liebsch G, Schmitz G, Coffing MJ, et al. Multicenter evaluation of a new inosine monophosphate dehydrogenase inhibition assay for quantification of total mycophenolic acid in plasma. *Ther Drug Monit* 2008;30:428–33.
- Marquet P, Premaud A, Sauvage F. Comparison of a new enzymatic assay with LC-MS/MS for the determination of plasma mycophenolate in patients with different graft types and associated immunosuppressants. [abstract] *Transplantation* 2006; 82:1005.
- Marquet P, Saint-Marcoux F, Premaud A, Sauvage FL, Jaqz-Aigrain E, Knoop C, et al. Performance of the new mycophenolate assay based on IMPDH enzymatic activity for pharmacokinetic investigations and setup of Bayesian estimators in different populations of allograft recipients. *Ther Drug Monit* 2009;31:443–50.
- Van Gelder T, Domke I, Engelmayer J, de FH, Kuypers D, Budde K, et al. Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. *Ther Drug Monit* 2009;31: 218–23.
- Peters FT. Method validation using LC-MS. In: Poletini A, editor. *Applications of LC-MS in toxicology*. London: Pharmaceutical Press; 2006; p. 71–96.
- Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. *Anal Chem* 2003;75:3019–30.
- Grubbs F. Procedures for detecting outlying observations in samples. *Technometrics* 1969;11:1–21.
- Lindner W, Wainer IW. Requirements for initial assay validation and publication in *J. Chromatography B. J Chromatogr B Biomed Sci Appl* 1998;707:1–2.
- Shen B, Li S, Zhang Y, Yuan X, Fan Y, Liu Z, et al. Determination of total, free and saliva mycophenolic acid with a LC-MS/MS method: application to pharmacokinetic study in healthy volunteers and renal transplant patients. *J Pharm Biomed Anal* 2009;50:515–21.
- Domke I, Engelmayer J, Langmann T, Liebsch G, Luthe H, Schmitz G, et al. Measurement of total and free mycophenolic acid with new enzyme receptor methods on COBAS Integra systems. *Clin Chem* 2005;51:C148.

23. Luthe H, Figurski M, Korecka M, Marquet P, Liebisch G, Cofing MJ, et al. Multicenter evaluation of the Roche total mycophenolic acid assay on Cobas Integra systems [poster]. 10th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology; Sep 9–14, 2007; Nice, France.
24. Taylor PJ. Matrix effects: the achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. *Clin Biochem* 2005;38:328–34.
25. Wieland E, Shipkova M, Schellhaas U, Schütz E, Niedmann PD, Armstrong VW, et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? *Clin Biochem* 2000;33:107–13.
26. Atcheson B, Taylor PJ, Mudge DW, Johnson DW, Pillans PI, Tett SE. Quantification of free mycophenolic acid and its glucuronide metabolite in human plasma by liquid-chromatography using mass spectrometric and ultraviolet absorbance detection. *J Chromatogr B Analyt Technol Biomed Life Sci* 2004;799:157–63.
27. Van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. *Ther Drug Monit* 2006;28:145–54.
28. Annesley TM, Clayton LT. Quantification of mycophenolic acid and glucuronide metabolite in human serum by HPLC-tandem mass spectrometry. *Clin Chem* 2005;51:872–7.
29. Brandhorst G, Streit F, Goetze S, Oellerich M, Armstrong VW. Quantification by liquid chromatography tandem mass spectrometry of mycophenolic acid and its phenol and acyl glucuronide metabolites. *Clin Chem* 2006;52:1962–4.
30. Figurski MJ, Korecka M, Fields L, Waligorska T, Shaw LM. High-performance liquid chromatography-mass spectroscopy/mass spectroscopy method for simultaneous quantification of total or free fraction of mycophenolic acid and its glucuronide metabolites. *Ther Drug Monit* 2009;31:717–26.
31. Hosotsubo H, Takahara S, Kokado Y, Permpongkosol S, Wang JD, Tanaka T, et al. Rapid and simultaneous determination of mycophenolic acid and its glucuronide conjugate in human plasma by ion-pair reversed-phase high-performance liquid chromatography using isocratic elution. *J Chromatogr B Biomed Sci Appl* 2001;753:315–20.
32. Khoschsorur G, Erwa W. Liquid chromatographic method for simultaneous determination of mycophenolic acid and its phenol- and acylglucuronide metabolites in plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2004;799:355–60.
33. Streit F, Shipkova M, Armstrong VW, Oellerich M. Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic acid. *Clin Chem* 2004;50:152–9.